Article

Higher Rates of COVID-19 but Less Severe Infections Reported for Patients on Il-4/Il-13 Blocker: A Big Data Analysis of the WHO Vigibase

2021-06-30

Abstract excerpt

Background: Dupilumab (Dupixent®) is a monoclonal antibody that inhibits IL-4 and IL-13 signaling used for the treatment of allergic diseases. Whilst biological therapy is generally associated with an increased risk of infectious disease, prior studies have suggested Dupilumab may be protective. <br><br>Objective: We investigated the link between Dupilumab therapy and SARS-CoV-2 infection.<br><br>Methods: We carry...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f329ff9e-c809-5630-af3a-2e189d2b4b82
DOI: 10.2139/ssrn.3869872

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Higher Rates of COVID-19 but Less Severe Infections Reported for Patients on Il-4/Il-13 Blocker: A Big Data Analysis of the WHO VigibaseDOI 10.2139/ssrn.3869872Read

COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort StudySemantic proximity Read

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platformSemantic proximity Read

Exploring drugs and vaccines associated with altered risks and severity of COVID-19: a UK Biobank cohort study of all ATC level-4 drug categoriesSemantic proximity Read

Multi-omics profiling identifies IL-13 signaling as a key mediator in Dupilumab-associated severe corneal injurySemantic proximity Read

Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approachSemantic proximity Read

UNVACCINATED PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES HAVE HETEROGENEOUS AND UNRELATED RISKS OF COVID INFECTION AND POOR OUTCOMESemantic proximity Read

A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic DiseasesSemantic proximity Read

Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large populationSemantic proximity Read

Estimating prevalence of immunocompromising conditions in Canada in 2022 using an administrative hospital databaseSemantic proximity Read

Real-world Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 PatientsSemantic proximity Read

Outcomes of Patients with COVID-19 in the Setting of Chronic Opioid Use DisorderSemantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read